Eyepoint Pharmaceuticals Stock Cash Per Share
| EYPT Stock | USD 8.95 0.60 7.19% |
Eyepoint Pharmaceuticals fundamentals help investors to digest information that contributes to Eyepoint Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eyepoint Stock. The fundamental analysis module provides a way to measure Eyepoint Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eyepoint Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Cash Per Share | 8.51 | 8.26 |
Eyepoint | Cash Per Share |
Eyepoint Pharmaceuticals Company Cash Per Share Analysis
Eyepoint Pharmaceuticals' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Eyepoint Pharmaceuticals Cash Per Share | 5.02 X |
Most of Eyepoint Pharmaceuticals' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eyepoint Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Eyepoint Cash Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Eyepoint Pharmaceuticals is extremely important. It helps to project a fair market value of Eyepoint Stock properly, considering its historical fundamentals such as Cash Per Share. Since Eyepoint Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eyepoint Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eyepoint Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Eyepoint Cash Per Share Historical Pattern
Today, most investors in Eyepoint Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Eyepoint Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Eyepoint Pharmaceuticals cash per share as a starting point in their analysis.
Eyepoint Pharmaceuticals Cash Per Share |
| Timeline |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
Eyepoint Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, Eyepoint Pharmaceuticals has a Cash Per Share of 5.02 times. This is 15.4% higher than that of the Pharmaceuticals sector and 15.94% higher than that of the Health Care industry. This indicator is about the same for all United States stocks average (which is currently at 5.01).
Eyepoint Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eyepoint Pharmaceuticals' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eyepoint Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eyepoint Pharmaceuticals by comparing valuation metrics of similar companies.Eyepoint Pharmaceuticals is currently under evaluation in cash per share category among its peers.
Eyepoint Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eyepoint Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eyepoint Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Eyepoint Fundamentals
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (2.27) % | ||||
| Operating Margin | (3.11) % | ||||
| Current Valuation | 379.32 M | ||||
| Shares Outstanding | 68.25 M | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 93.43 % | ||||
| Number Of Shares Shorted | 9.68 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 2.79 X | ||||
| Price To Sales | 12.47 X | ||||
| Revenue | 46.02 M | ||||
| Gross Profit | 26.95 M | ||||
| EBITDA | (69 M) | ||||
| Net Income | (70.8 M) | ||||
| Cash And Equivalents | 171.17 M | ||||
| Cash Per Share | 5.02 X | ||||
| Total Debt | 5.47 M | ||||
| Debt To Equity | 0.30 % | ||||
| Current Ratio | 6.16 X | ||||
| Book Value Per Share | 4.09 X | ||||
| Cash Flow From Operations | 1.88 M | ||||
| Short Ratio | 10.40 X | ||||
| Earnings Per Share | (1.99) X | ||||
| Target Price | 33.45 | ||||
| Number Of Employees | 121 | ||||
| Beta | 1.52 | ||||
| Market Capitalization | 569.9 M | ||||
| Total Asset | 355.18 M | ||||
| Retained Earnings | (742.15 M) | ||||
| Working Capital | 281.54 M | ||||
| Current Asset | 15.08 M | ||||
| Current Liabilities | 11.26 M | ||||
| Net Asset | 355.18 M |
About Eyepoint Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eyepoint Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eyepoint Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eyepoint Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.